Methods of use of anti-sortilin antibodies
AssigneeAlector LLC
InventorsRobert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Herve RHINN
Life of this patent
Estimating the term…
Loading patent…
AssigneeAlector LLC
InventorsRobert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Herve RHINN
Estimating the term…
The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
A method of treating and/or delaying the progression of a disease or injury in an individual, comprising administering to the individual an anti-Sortilin antibody intravenously at a dose of at least about 30 mg/kg once every four weeks or more frequently, wherein the antibody comprises:
A method of monitoring treatment of an individual being administered an anti-Sortilin antibody, comprising measuring the level of one or more proteins in a sample from the individual before and after the individual has received one or more doses of an anti-Sortilin antibody, wherein the one or more proteins are selected from the group consisting of CTSB, SPP1, NAGK, YWHAE, AIF1, CSF1, CHIT1, LY86, neurofilament light chain (NfL), and CD86.
46-53. (canceled)
Dependencies are inferred from the claim text.